All News

Fentanyl citrate (Actiq) is an opioid agonist indicated for the management of breakthrough pain in cancer patients.

Lung Support Formula is comprised of natural extracts to help promote lung health.

The step-up dosing approach with glofitamab in a phase 1 trial enabled researchers to minimize cytokine release syndrome while maximizing outcomes.

Evidence suggests there are benefits to a more holistic mentoring approach.

Many health care systems are turning to biosimilars to provide clinical outcomes that are similar to those provided by reference products, but at a reduced cost.

Jeff Betcher, BSPharm, MBA, director of pharmacy at Mayo Clinic in Arizona, discusses how automated chemotherapy dose rounding can help decrease drug waste and cost.

As best practices are established throughout the specialty pharmacy’s entire network, better patient outcomes become possible.

Expert notes that any unease around the use of radiopharmaceuticals is just due to a lack of familiarity with the field.

Training pharmacy technicians to evaluate tasks such as appropriate site of care and plan benefits can reduce the workload for the pharmacist.

Certain areas of chapters written by US Pharmacopeia have evolved since being made official and have become standard best practices today.

Case highlights the need to stop, listen, and investigate when patients or parents express a safety concern.

Lyrica is indicated for neuropathic pain associated with diabetic peripheral neuropathy, postherpetic neuralgia, fibromyalgia, spinal cord injury nerve pain, and pain after shingles in adult patients.

Better Nail is an anti-fungal product for fungus under and around the nails.

Angela Livingood, PharmD, MHA, BCGP, CPHQ, diversion specialist at Novant Health, discusses what drug diversion is and why it is important for pharmacists to be aware of it.

Brooke Looney, PharmD, certified specialty pharmacist in the Oncology Clinic at Vanderbilt Specialty Pharmacy, discusses medication changes and adverse events for patients starting encorafenib and binimetinib.

Shields Health Solutions poster presentations highlight a comprehensive approach to specialty patient care and successful results from an expanded offering of instructional programs.

Nicholas Robert, MD, chief medical officer at Ontada, discussed disparities in biomarker testing and how they are being addressed.

New recommendations provide some harmonization to make it easier for clinicians to lower the barriers to assessing and identifying eligible patients for the pneumococcal vaccine.

Connection with others and staying on top of your mental well-being are just as important as physical health.

Early intervention, prudent use of antibiotics can help patients treat condition, speed recovery.

COVID-19 vaccine recommendations have parallel tracks for adults and parallel tracks for children broken down into whether an individual is immunocompromised.

Baricitinib (Olumiant; Eli Lilly and Company) is the first systemic treatment to be approved by the FDA for severe alopecia areata, which affects an estimated 300,000 patients in the United States.

Raloxifene hydrochloride (Evista) is indicated for the treatment and prevention of osteoporosis in postmenopausal women, as well as to lower the risk of invasive breast cancer in postmenopausal women with osteoporosis.

Kerasal helps to reduce discoloration and thickness of nails and to hydrate and exfoliate brittle nails.

Kayla Cierniak, PharmD, MS, BCPS, FISMP, medication safety officer in oncology at Seidman Cancer Center discusses the Bar Code Medication Administration and some challenges the initiative faced.

Arpit Mehta, PharmD, MPh, MHA, director of Pharmacy at Allegheny General Hospital, discusses innovations in health-system patient care models to improve patient outcomes.

Katherine Harte, PharmD, a PGY2 ambulatory care pharmacy resident at the Rhode Island Hospital in Providence, Rhode Island, discusses the impact of pharmacist management on SGLT2 inhibitors and GLP-1 receptor agonist utilization in patients with type 2 diabetes mellitus.

The treatment also significantly reduces the risk of progression or death and prolonged median PFS compared with fulvestrant in all individuals without prior chemotherapy, the analysis shows.